18 February 2025

Registration of new share capital

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 6 February 2025 regarding the final result of the subsequent offering in the Company, where a total of 5,500,000 new shares were subscribed and allocated at a subscription price of NOK 2 per share.

The share capital increase pertaining to the subsequent offering has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s registered share capital is NOK 9,774,334.30 divided into 97,743,343 shares, each with a nominal value of NOK 0.10.

The new shares will be issued in the Norwegian Central Securities Depository (ES-OSL) on the same ISIN as the other shares in the Company (ISIN NO 0010779341) and are expected to be delivered to the respective subscribers’ ES-OSL accounts on or about 18 February 2025.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

The Share

IR Contact

+47 22 18 33 05

Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close